Meeting
2024 ASCO Annual Meeting
A single-cell multiomics analysis of IRF4 in mediating treatment resistance in ibrutinib-treated chronic lymphocytic leukemia (CLL).
Authors
Alina S. Gerrie
BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada
Alina S. Gerrie , Gerben Duns , Yifan Yin , Shinya Rai , Laura Hilton , Barbara Meissner , Hisae Nakamura , Luke O'Brien , Merrill Boyle , Ryan Morin , Aaron Marshall , Spencer B. Gibson , David W. Scott , James B. Johnston , Christian Steidl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7051)
DOI
10.1200/JCO.2024.42.16_suppl.7051
Abstract #
7051
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer.
First Author: Cayce Ben Nawaf
Poster
2022 ASCO Annual Meeting
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Don A. Stevens
Poster
2021 ASCO Annual Meeting
Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity.
First Author: Issam Hamadeh
Poster
2015 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).
First Author: Meletios A. Dimopoulos